Starcoin Deepens Johns Hopkins Ties in Five-Year Diabetes Research Pact

Innovative Pharmaceutical Biotech ( (HK:0399) ) has shared an announcement.

Starcoin Group Limited has signed a five-year Sponsored Research and Strategic Advisory Agreement with the Scaling Lab at Johns Hopkins University School of Medicine to deepen their collaboration on cardiometabolic and diabetes-related research. Under the deal, the lab will conduct non-clinical research into cardiovascular and cardiometabolic diseases, including diabetes and non-injectable diabetes treatment pathways, while Dr. Hunter Young’s team will advise the group on oral diabetes drugs, oral peptide therapeutics and drug-delivery systems, with Johns Hopkins retaining intellectual property ownership but granting Starcoin preferential licensing rights. The arrangement underpins Starcoin’s strategy to enhance the scientific quality and commercial prospects of its flagship oral insulin program and broader R&D business, aligning the company with a globally recognised medical research institution and potentially strengthening its long-term competitive position in diabetes treatment.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, operates an R&D-focused biopharmaceutical business with a primary emphasis on developing an oral insulin product and other oral diabetes and peptide therapeutics. Since acquiring Smart Ascent Limited in 2014, the group has positioned its research and development operations around cardiometabolic and diabetes-related treatments, despite pandemic-related disruptions, with the goal of advancing clinical trials and eventual commercialisation of its pipeline products.

Average Trading Volume: 22,229,405

Technical Sentiment Signal: Sell

Current Market Cap: HK$218.6M

Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.